A Pharmacokinetic Study of Plerixafor in Subjects with Varying Degrees of Renal Impairment

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages 95-101

  MacFarland, Ronald ^a   Hard, Marjie L ^a   Scarborough, Robert ^b   Badel, Karin ^a   Calandra, Gary ^a  

^a GENZYME CORPORATION   (United States)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PLERIXAFOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERVENTILATION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; KIDNEY DISEASE; LEUKOCYTOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MUSCLE SPASM; NEUROLOGIC DISEASE; OPEN STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SKIN TINGLING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; COHORT STUDIES; CREATININE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; RECEPTORS, CXCR4; RENAL INSUFFICIENCY;

EID: 72649086683     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.09.003     Document Type: Article

References (11)

1. In: Horowitz M. (Ed). Uses and Growth of Hematopoietic Cell Transplantation (2004), Blackwell, Boston
2. + hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 1 (2004) 165-172
3. Inc S. SDZ SID-791: Absorption and disposition in dogs following single subcutaneous and intravenous doses of [14C]SDZ SID-791-ch. Study 9608.0256 (1995)
4. San Miguel J.F., Lahuerta J.J., Garcia-Sanz R., et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation?. Hematol J 1 (2000) 28-36
5. Hendrix C., Flexner C., MacFarland R., et al. Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 44 (2000) 1667-1673
6. Stewart D.A., Smith C., MacFarland R., et al. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 15 (2009) 39-46
7. Cashen A., Lopez S., Gao F., et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 14 (2008) 1253-1261
8. + hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther 77 (2005) 427-436
9. Genzyme Corporation. Mozobil (plerixafor injection) package insert (2008), Genzyme Corporation, Cambridge, MA
10. Douglas K.W., Hayden P.J., O'Dwyer M.E., et al. Plerixafor plus G-CSF is effective without significant toxicity in PBSC mobilisation from myeloma patients with dialysis-dependent renal failure who have failed to mobilise by conventional means: an initial series of three patients (abstract 600). Presented at the 35th Annual Meeting of the European Group for Blood and Marrow Transplantation (2009)
11. Liles W.C., Broxmeyer H.E., Rodger E., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 102 (2003) 2728-2730